$CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Healthcare
Sector
Biotechnology
Industry
Eric So
CEO
50
Employees
$8.28
Current Price
$413.02M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 2 | 3 | $3,733,050.00 | 300,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 2 | 6 | $7,241,705.00 | 595,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 2 | 7 | $8,284,382.00 | 685,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 7 | $8,284,382.00 | 685,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 7 | $8,284,382.00 | 685,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Glavine Paul Chief Growth Officer | Purchase | 100,000 | $12.47 | $1,247,190.00 | View Details |
| Sep 8, 2026 | Glavine Paul Chief Growth Officer | Purchase | 100,000 | $12.47 | $1,247,190.00 | View Details |
| Sep 8, 2026 | So Eric H. L. Director | Purchase | 100,000 | $12.39 | $1,238,670.00 | View Details |
| Sep 4, 2026 | So Eric H. L. Director | Purchase | 100,000 | $12.09 | $1,208,900.00 | View Details |
| Sep 3, 2026 | Glavine Paul Chief Growth Officer | Purchase | 100,000 | $11.78 | $1,178,280.00 | View Details |
| Sep 1, 2026 | So Eric H. L. Director | Purchase | 95,000 | $11.80 | $1,121,475.00 | View Details |
| Aug 31, 2026 | Glavine Paul Chief Growth Officer | Purchase | 90,000 | $11.59 | $1,042,677.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals